/
INGN
$6.93-$0.01 (-0.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$187.9M
27M shares
52-week range
$5.34 – $9.13
42% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
1.26%
Moderate
Price (6 mo)
Loading chart…
Change$-58.24
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $358.1M | $361.9M | $308.5M | $358.0M | $377.2M | $315.7M | $335.7M | $348.7M |
| Cost of revenue | $179.5M | $190.1M | $170.3M | $181.5M | $223.7M | $189.0M | $181.0M | $182.8M |
| Gross profit | $178.6M | $171.9M | $138.2M | $176.5M | $153.5M | $126.7M | $154.7M | $165.9M |
| Gross margin | 49.9% | 47.5% | 44.8% | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| R&D | $7.0M | $9.4M | $14.1M | $16.6M | $21.9M | $20.8M | $21.6M | $19.4M |
| Operating income | $37.9M | $19.8M | −$12.0M | $9.2M | −$85.2M | −$109.4M | −$42.5M | −$30.2M |
| EBITDA | $49.2M | $33.6M | $6.6M | $30.3M | −$9.6M | −$58.3M | −$15.5M | −$2.7M |
| Net income | $51.8M | $20.9M | −$5.8M | −$6.3M | −$83.8M | −$102.4M | −$35.9M | −$22.7M |
| Net margin | 14.5% | 5.8% | -1.9% | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (diluted) | 2.30 | 0.94 | -0.27 | -0.28 | -3.67 | -4.42 | -1.52 | -0.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $369M | $-0.78 | $-0.79–$-0.78 | 1 |
| 2027 | $397M | $-0.47 | $-0.47–$-0.46 | 1 |
| 2028 | $417M | $-0.33 | $-0.51–$-0.15 | 2 |
| 2029 | $455M | $0.05 | $0.05–$0.05 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Inogen Inc
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
www.inogen.com- Employees
- 753
- IPO / List date
- Feb 14, 2014
- HQ
- BEVERLY, MA
Held by traders on TradeandTell
No one on the platform currently holds INGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 478,800 | $3.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INGN yet.
